人类免疫缺陷病毒（HIV）感染者中 2019 年冠状病毒病（COVID-19）mRNA 疫苗诱导免疫的衰减。
Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.
机构信息
Department of Medicine, Johns Hopkins Medicine.
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.
出版信息
AIDS. 2022 Jul 15;36(9):1315-1317. doi: 10.1097/QAD.0000000000003263.
Abstract
Current coronavirus disease 2019 (COVID-19) mRNA vaccines induce robust SARS-CoV-2-specific humoral and cellular responses in people with HIV (PWH). However, the rate of decay of effector immune responses has not been studied in these individuals. Here, we report a significant waning of antibody responses but persistent T-cell responses 6 months post vaccination in virally suppressed PWH with high CD4+ T-cell counts. These responses are comparable with those seen in healthy donors.
摘要
目前，针对 2019 年冠状病毒病（COVID-19）的 mRNA 疫苗可在人类免疫缺陷病毒（HIV）感染者（PWH）体内诱导出针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的体液和细胞应答。然而，这些人群中效应免疫应答的衰减速度尚未得到研究。在此，我们报告了在病毒得到抑制且 CD4+T 细胞计数较高的 PWH 中，抗体应答在接种后 6 个月显著下降，但 T 细胞应答持续存在。这些应答与健康供者所见的应答相当。
相似文献
1
Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.人类免疫缺陷病毒（HIV）感染者中 2019 年冠状病毒病（COVID-19）mRNA 疫苗诱导免疫的衰减。
AIDS. 2022 Jul 15;36(9):1315-1317. doi: 10.1097/QAD.0000000000003263.
2
Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.在 HIV 感染者中，不同的 SARS-CoV-2 疫苗平台可诱导产生稳健的疫苗诱导的体液免疫和细胞免疫反应。
Microbiol Spectr. 2023 Jun 15;11(3):e0115523. doi: 10.1128/spectrum.01155-23. Epub 2023 May 11.
3
A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.一种双抗原自扩增 RNA SARS-CoV-2 疫苗可诱导强烈的体液和细胞免疫应答，并通过 T 细胞介导的免疫来预防 SARS-CoV-2 变体。
Mol Ther. 2022 Sep 7;30(9):2968-2983. doi: 10.1016/j.ymthe.2022.04.014. Epub 2022 Apr 20.
4
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).BNT162b2 mRNA 疫苗在人类免疫缺陷病毒（HIV）感染者中引发强烈的体液和细胞免疫应答。
Clin Infect Dis. 2022 Apr 9;74(7):1268-1270. doi: 10.1093/cid/ciab648.
5
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
6
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.抗 CD20 治疗史患者的体液和细胞免疫轨迹以及对第三剂 SARS-CoV-2 mRNA 疫苗的反应。
RMD Open. 2022 Mar;8(1). doi: 10.1136/rmdopen-2021-002166.
7
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.单次接种核苷修饰的 mRNA 疫苗可在小鼠中诱导针对 SARS-CoV-2 的强烈细胞和体液免疫应答。
Immunity. 2020 Oct 13;53(4):724-732.e7. doi: 10.1016/j.immuni.2020.07.019. Epub 2020 Jul 30.
8
Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine.在感染 HIV 的人群中，接种严重急性呼吸综合征冠状病毒 2 疫苗后的替代中和反应：灭活疫苗和 mRNA 疫苗之间的比较。
AIDS. 2022 Jul 15;36(9):1255-1264. doi: 10.1097/QAD.0000000000003237. Epub 2022 Apr 23.
9
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
10
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.BNT162b2 mRNA 疫苗接种后细胞和体液功能反应在 COVID-19 初治和恢复期患者中具有纵向差异。
Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21.
引用本文的文献
1
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.针对不同免疫功能低下状况个体的新型冠状病毒mRNA疫苗纵向免疫原性队列研究：免疫反应的异质性及奥密克戎适应性加强剂量的关键作用
EBioMedicine. 2025 Mar;113:105577. doi: 10.1016/j.ebiom.2025.105577. Epub 2025 Feb 4.
2
SARS-CoV-2 Humoral and Cellular Immune Responses in People Living with HIV.感染艾滋病毒者的新型冠状病毒2型体液免疫和细胞免疫反应
Vaccines (Basel). 2024 Jun 16;12(6):663. doi: 10.3390/vaccines12060663.
3
Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV.HIV感染者接种mRNA疫苗后抗SARS-CoV-2免疫原性的长期评估
Vaccines (Basel). 2023 Nov 22;11(12):1739. doi: 10.3390/vaccines11121739.
4
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.患有癌症、艾滋病毒或实体器官移植的免疫功能低下个体中的SARS-CoV-2特异性T细胞反应。
Pathogens. 2023 Feb 3;12(2):244. doi: 10.3390/pathogens12020244.
5
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?HIV/AIDS 与 COVID-19 之间的免疫相互作用：火上浇油？
Curr HIV/AIDS Rep. 2023 Apr;20(2):51-75. doi: 10.1007/s11904-023-00647-z. Epub 2023 Jan 21.
6
Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Shedding in a Patient With AIDS: Case Report and Review of the Literature.一名艾滋病患者出现严重急性呼吸综合征冠状病毒2（SARS-CoV-2）Delta变异株的长期脱落：病例报告及文献综述
Open Forum Infect Dis. 2022 Sep 17;9(9):ofac479. doi: 10.1093/ofid/ofac479. eCollection 2022 Sep.
Zotero 插件